Valuation: Plus Therapeutics, Inc.

Market Cap 25.74M 22.53M 20.81M 19.14M 36.09M 2.48B 36.91M 248M 97.57M 1.21B 96.67M 94.54M 4.18B P/E 2026 *
-0.95x
P/E 2027 * -1.56x
Enterprise Value 25.74M 22.53M 20.81M 19.14M 36.09M 2.48B 36.91M 248M 97.57M 1.21B 96.67M 94.54M 4.18B EV / Sales 2026 *
4.09x
EV / Sales 2027 * 1.34x
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day-4.10%
1 week-6.50%
Current month-14.42%
1 month-10.95%
3 months-41.47%
6 months-48.02%
Current year-70.80%
1 week 3.58
Extreme 3.58
4.42
1 month 3.58
Extreme 3.58
4.51
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
975
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
Change 5-day change 1-year change 3-year change Capi.($)
-4.10%-6.50%-59.73%-93.07% 25.74M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average -0.36%-0.63%+52.01%+77.15% 24.37B
Weighted average by Cap. -0.05%-0.18%+79.43%+123.29%

Financials

2026 *2027 *
Net sales 6.3M 5.51M 5.09M 4.68M 8.83M 606M 9.03M 60.66M 23.86M 296M 23.64M 23.12M 1.02B 19.14M 16.75M 15.47M 14.24M 26.83M 1.84B 27.44M 184M 72.55M 901M 71.88M 70.3M 3.11B
Net income -26.8M -23.45M -21.66M -19.93M -37.57M -2.58B -38.42M -258M -102M -1.26B -101M -98.43M -4.35B -18.45M -16.15M -14.92M -13.72M -25.87M -1.78B -26.46M -178M -69.95M -869M -69.3M -67.78M -3B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
17/07/26 US$3.740 -4.10% 215,179
16/07/26 US$3.900 -4.41% 81,584
15/07/26 US$4.080 -4.67% 154,136
14/07/26 US$4.280 +2.64% 370,991
13/07/26 US$4.170 +4.25% 375,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.740USD
Average target price
36.00USD
Spread / Average Target
+862.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock